Timothatel Posted - 1 day ago

[$FOLD $HCM] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

PeedyWeedy Posted - 3 days ago

$HCM Will phase 3 data on the upcoming conference around December 8th likely move the stock price a lot?

Amudlino Posted - 5 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $HCM $XENE

DonCorleone77 Posted - 2 weeks ago

$HCM Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial Hutchmed announced that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by Hutchmed will be presented at the American Society of Hematology, or ASH, annual meeting taking place on December 7-10 in San Diego and the European Society for Medical Oncology, or ESMO, Asia Congress, taking place on December 6-8 in Singapore. Long-term safety and efficacy data from a follow-on, open-label sub-study of the extension stage of ESLIM-01 Phase III study of sovleplenib in adult patients with chronic primary immune thrombocytopenia, or ITP, in China will be reported at the 2024 ASH Annual Meeting. At data cut-off on January 31, a total of 179 patients were treated with at least one dose of sovleplenib. 55.3% of the patients were still on the treatment in the sub-study, with a median duration of exposure of 56.6 weeks. The follow-on sub-study data demonstrated that long-term treatment with sovleplenib was effective in increasing and maintaining platelet count in adults with chronic primary ITP in China. In the overall population, the overall response was achieved by 81% of the patients, with a durable response rate of 51.4% and long-term durable response rate of 59.8%. The median cumulative duration of platelet count of greater than or equal to 50x10/L was 38.9 weeks. The long-term treatment was well tolerated, with a safety profile consistent with previous studies and no new safety signals were identified.

Deoyesconsult Posted - 10/30/24

$HCM Zodiac Signs to Win the Jackpot on November 1st, 2024! New Super Moon https://youtu.be/Uroyg4s7JAU?si=S4PdQU9MSUgUpX0T

WeeklyTrader Posted - 1 month ago

Who's ready for $HCM's big breakout? RSI: 54.3% 50-day MA: $18.4 200-day MA: $17.42

DonCorleone77 Posted - 1 month ago

$HCM $AZN Hutchmed announces results from SAVANNAH trial Hutchmed (HCM) announced high-level results from the SAVANNAH Phase II trial that showed Tagrisso plus Orpathys demonstrated a high, clinically meaningful and durable objective response rate, or ORR, for patients with epidermal growth factor receptor-mutated, or EGFRm, non-small cell lung cancer, or NSCLC, with high levels of MET overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with Tagrisso. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities. In 2023, Tagrisso plus Orpathys received Fast Track designation from the FDA in this setting. Orpathys is an oral, potent, and highly selective MET tyrosine kinase inhibitor being jointly developed by AstraZeneca (AZN) and Hutchmed and commercialized by AstraZeneca. It is approved in China for the treatment of patients with NSCLC with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. While EGFR-targeted therapy can provide a substantial survival benefit to patients with EGFRm NSCLC, most will eventually develop resistance to their treatment, with MET being a common resistance biomarker. Among patients screened for enrollment in SAVANNAH, an estimated 62% had tumors with MET overexpression and/or amplification, and approximately 34% met the defined high MET level cut-off upon clinical progression. The safety and tolerability of Tagrisso plus Orpathys was consistent with the known safety profiles of the combination and each treatment alone. No new safety signals were identified. On August 2022, initial positive ORR results from the SAVANNAH trial were presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer, or WCLC. The global SAFFRON Phase III trial sponsored by AstraZeneca will further assess the Tagrisso plus Orpathys combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following Tagrisso. Patients are being prospectively selected using the high MET level cut-off identified in SAVANNAH.

interestingtimes Posted - 1 month ago

$HCM more breakthroughs announced in lung cancer trials https://www.hutch-med.com/news/news-press-releases/#

interestingtimes Posted - 1 month ago

$HCM more breakthroughs announced today in lung cancer support https://www.hutch-med.com/news/news-press-releases/#

vu_jade Posted - 1 month ago

$HCM on watch

MBSB Posted - 09/25/24

$HCM would Merck’s failure affect this?

jParkz Posted - 09/24/24

$HCM News out HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda https://marketwirenews.com/news-releases/hutchmed-announces-japan-approval-for-fruzaqla-xae-f-7039042570994119.html $HCM

Stock_Titan Posted - 09/24/24

$HCM HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda https://www.stocktitan.net/news/HCM/hutchmed-announces-japan-approval-for-fruzaqla-r-fruquintinib-0fg3uz47ihiu.html

Stocksrunner Posted - 2 months ago

🚨 5 Hot Stocks to Watch Monday: $GEV, $S, $HCM, $ACGL & $KNX – Trend Reversals, Breakouts, & Big Moves Ahead! 📈🔥 stocksrunner.com/posts/1144

Stock_Titan Posted - 2 months ago

$HCM HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer https://www.stocktitan.net/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-juhjs30tncua.html

BioTechChap Posted - 2 months ago

$ZLAB $IMAB $HCM "Cheapest Ever"

Stocksrunner Posted - 08/30/24

Friday Pre-Market Movers: 5 Must-Watch Stocks! 🚀 $MNSO jumps on Q2 earnings & buyback $JKS surges after reaffirming FY24 outlook $HCM tanks after pulling cancer drug application $LULU rebounds on earnings & Cramer’s call $EBS skyrockets after FDA approval https://stocksrunner.com/posts?id=1095

Stock_Titan Posted - 08/29/24

$HCM HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China https://www.stocktitan.net/news/HCM/hutchmed-provides-update-on-fruquintinib-for-second-line-gastric-l31wjwtg732e.html

Stock_Titan Posted - 07/31/24

$HCM HUTCHMED Reports 2024 Interim Results and Provides Business Updates https://www.stocktitan.net/news/HCM/hutchmed-reports-2024-interim-results-and-provides-business-5zgw8fxjjdoz.html

StockInvest_us Posted - 07/29/24

Signal alert: $HCM - PivotPoint bottom https://stockinvest.us/l/cmUd2z8q6G

StockInvest_us Posted - 4 months ago

Signal alert: $HCM - PivotPoint bottom https://stockinvest.us/l/jw4sAHI5Oo

Doozio Posted - 4 months ago

$HCM they tried to 🐑 it last week. Bahhht they bullish engulfed it cuz it’s 🧠⏰

ObeCalp Posted - 4 months ago

$HCM and $LEGN both Chinese biotechs getting investor interest the last couple days. Something seems up.

falconfly1 Posted - 4 months ago

$EYEN $GRFS and $ASRT and $HCM and $THTX What is new and opportunity in $EYEN? 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.

Doozio Posted - 4 months ago

$HCM or off da 200d as XBI n KWEB are still in da chop chop bahhhht da huckleberries n 🧠⏰ are comin

RockyTSTH Posted - 4 months ago

$HCM HUTCHMED shares are trading higher after the company announced that its NDA for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status. BZ Wire

OpenOutcrier Posted - 4 months ago

$HCM (+5.1% pre) HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status https://ooc.bz/l/36954

Stock_Titan Posted - 4 months ago

$HCM HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status https://www.stocktitan.net/news/HCM/hutchmed-announces-nda-acceptance-in-china-for-tazemetostat-for-the-wr2f5st7jhrc.html

StockInvest_us Posted - 4 months ago

Signal alert: $HCM - Possible Runner https://stockinvest.us/l/fCfigN3LxU

Stock_Titan Posted - 06/26/24

$HCM HUTCHMED to Announce 2024 Half-Year Financial Results https://www.stocktitan.net/news/HCM/hutchmed-to-announce-2024-half-year-financial-x7hypwqe7py0.html